Scholarlink

Objective <p>To provide the first nationwide description of biologic and targeted synthetic DMARD (b/tsDMARD) use among Estonian patients with rheumatoid arthritis (RA), focusing on treatment effectiveness, persistence, and reasons for discontinuation across sequential lines of therapy.</p> Methods <p>Data were obtained from the Estonian Biologic Therapy Registry covering years 2006–2022. All adult RA patients who had received at least one dose of a b/tsDMARD were included. Effectiveness at 6 months was evaluated using DAS28-CRP as a continuous measure (ΔDAS28) and categorical response definitions: remission (DAS28 ≤ 2.6), low disease activity (LDA; DAS28 &gt; 2.6 and ≤ 3.2), and EULAR response criteria. Treatment persistence was analyzed using Kaplan–Meier estimates, and reasons for discontinuation were categorized systematically.</p> Results <p>A total of 1,074 patients were analysed (78% female, mean age 53.7 years, 85% seropositive). Mean baseline DAS28-CRP was 5.1. The mean 6-month reduction in DAS28-CRP during first-line therapy was ~ 2.2 points. Remission was achieved in 35–46% of patients across treatment lines 1–5, with overlapping confidence intervals, while LDA occurred in about 12–22% of patients. Drug survival was comparable between treatment lines: 60% of patients remained on therapy at 2 years, and the median time to discontinuation for first-line therapy was 1.66 years. Most patients initiated therapy with a TNF inhibitor and many continued within the same class before switching to IL-6 inhibitors, rituximab, or JAK inhibitors. The main reasons for discontinuation were loss or lack of efficacy (~ 50%) and adverse events (~ 27%), predominantly allergic reactions and infections.</p> Conclusions <p>In real-world Estonian RA practice, biologic and targeted therapies were effective across multiple treatment lines, with the greatest improvement observed during first-line therapy and sustained clinical benefit in later lines. Treatment persistence remained stable despite multiple switches, and the distribution of discontinuation causes mirrored other European registries. These findings support the continued value of sequential b/tsDMARD therapy in achieving disease control among patients with difficult-to-treat RA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Remission and treatment persistence during sequential therapy in rheumatoid arthritis: results from the Estonian Biologic Treatment Registry

  • 期刊论文

  • 发表日期：

    2026年3月21日

查看全文
  • Katrin Ulst,
  • Sigrid Vorobjov,
  • Karin Laas,
  • Raili Müller

摘要

Objective

To provide the first nationwide description of biologic and targeted synthetic DMARD (b/tsDMARD) use among Estonian patients with rheumatoid arthritis (RA), focusing on treatment effectiveness, persistence, and reasons for discontinuation across sequential lines of therapy.

Methods

Data were obtained from the Estonian Biologic Therapy Registry covering years 2006–2022. All adult RA patients who had received at least one dose of a b/tsDMARD were included. Effectiveness at 6 months was evaluated using DAS28-CRP as a continuous measure (ΔDAS28) and categorical response definitions: remission (DAS28 ≤ 2.6), low disease activity (LDA; DAS28 > 2.6 and ≤ 3.2), and EULAR response criteria. Treatment persistence was analyzed using Kaplan–Meier estimates, and reasons for discontinuation were categorized systematically.

Results

A total of 1,074 patients were analysed (78% female, mean age 53.7 years, 85% seropositive). Mean baseline DAS28-CRP was 5.1. The mean 6-month reduction in DAS28-CRP during first-line therapy was ~ 2.2 points. Remission was achieved in 35–46% of patients across treatment lines 1–5, with overlapping confidence intervals, while LDA occurred in about 12–22% of patients. Drug survival was comparable between treatment lines: 60% of patients remained on therapy at 2 years, and the median time to discontinuation for first-line therapy was 1.66 years. Most patients initiated therapy with a TNF inhibitor and many continued within the same class before switching to IL-6 inhibitors, rituximab, or JAK inhibitors. The main reasons for discontinuation were loss or lack of efficacy (~ 50%) and adverse events (~ 27%), predominantly allergic reactions and infections.

Conclusions

In real-world Estonian RA practice, biologic and targeted therapies were effective across multiple treatment lines, with the greatest improvement observed during first-line therapy and sustained clinical benefit in later lines. Treatment persistence remained stable despite multiple switches, and the distribution of discontinuation causes mirrored other European registries. These findings support the continued value of sequential b/tsDMARD therapy in achieving disease control among patients with difficult-to-treat RA.